Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer

Bookmark and Share
Published: 30 Sep 2019
Views: 566
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain

Dr Enrique Grande presents data from the IMvigor130 trial during a press conference at the 2019 ESMO congress.

This was a trial evaluating first-line immunotherapy and chemotherapy instead of chemotherapy alone in patients with metastatic urothelial cancer.

Watch Dr Enrique Grande's interview with ecancer here.

Watch Dr Ignacio Duran's comment here

Read more about the study here.